Literature DB >> 27966024

Comparing the symptom experience of cancer patients and non-cancer patients.

Teresa L Deshields1, Valentina Penalba2, Jingxa Liu3, James Avery4.   

Abstract

PURPOSE: Symptom burden is an established concept in oncology encompassing the presence and severity of symptoms experienced by cancer patients. Few studies have examined differences in symptom burden between cancer patients and non-cancer patients. This study seeks to examine the differences in symptom burden between cancer patients (CP) and non-cancer patients (NCP) in order to better understand symptom burden in both populations.
METHODS: Two groups of patients completed the Memorial Symptom Assessment Scale: 301 patients from a general medical clinic and 558 cancer patients from a cancer tumor registry. Participants provided demographic information-age, race/ethnicity, and sex and completed the Memorial Symptom Assessment Scale. Medical comorbidity was also measured.
RESULTS: Most symptoms were more common in CP, except for pain, which was more prevalent in the NCP (45% of CP vs. 54% of NCP, p < .05). There was no difference in prevalence for the following symptoms: dry mouth, mouth sores, feeling nervous, worry, cough, and dizziness. The CP had greater mean MSAS Total scores (0.53 vs. 0.43, p < .01), number of symptoms (9.11 vs. 6.13, p < .01), and psychological subscale scores (0.77 vs. 0.64, p < .05). There was no difference by group in the physical nor the GDI subscale scores.
CONCLUSION: The results of this study support the perception that cancer patients have greater symptom burden. There were some unexpected results, particularly in terms of pain, which was more common in NCP and other symptoms that were experienced equally in both patient populations.

Entities:  

Keywords:  Cancer; Memorial symptom assessment scale; Non-cancer patients; Pain; Symptom prevalence

Mesh:

Year:  2016        PMID: 27966024     DOI: 10.1007/s00520-016-3498-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  34 in total

1.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Authors:  Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2014-09-29       Impact factor: 13.506

2.  Comparison of the Adult Comorbidity Evaluation 27 and the Charlson Comorbidity indices in patients with laryngeal squamous cell carcinoma.

Authors:  V S Nesic; Z M Petrovic; S B Sipetic; S D Jesic; I A Soldatovic; D A Kastratovic
Journal:  J Laryngol Otol       Date:  2012-03-26       Impact factor: 1.469

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Disagreement in doctor's and patient's rating about medically unexplained symptoms and health care use.

Authors:  Sarah Schumacher; Winfried Rief; Elmar Brähler; Alexandra Martin; Heide Glaesmer; Ricarda Mewes
Journal:  Int J Behav Med       Date:  2013-03

5.  Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer.

Authors:  Claudia Bausewein; Sara Booth; Marjolein Gysels; Robert Kühnbach; Birgit Haberland; Irene J Higginson
Journal:  J Palliat Med       Date:  2010-09       Impact factor: 2.947

Review 6.  Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

Authors:  M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn
Journal:  Ann Oncol       Date:  2007-03-12       Impact factor: 32.976

7.  Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale.

Authors:  Joan E Tranmer; Daren Heyland; Debra Dudgeon; Dianne Groll; Mae Squires-Graham; Kathy Coulson
Journal:  J Pain Symptom Manage       Date:  2003-05       Impact factor: 3.612

Review 8.  Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management.

Authors:  Mark S Chambers; Adam S Garden; Merrill S Kies; Jack W Martin
Journal:  Head Neck       Date:  2004-09       Impact factor: 3.147

9.  Living with breathlessness: a survey of caregivers of breathless patients with lung cancer or heart failure.

Authors:  Farida A Malik; Marjolein Gysels; Irene J Higginson
Journal:  Palliat Med       Date:  2013-05-23       Impact factor: 4.762

Review 10.  Symptom burden and quality of life in survivorship: a review of the literature.

Authors:  Horng-Shiuann Wu; Janet K Harden
Journal:  Cancer Nurs       Date:  2015 Jan-Feb       Impact factor: 2.592

View more
  3 in total

Review 1.  Yoga for symptom management in oncology: A review of the evidence base and future directions for research.

Authors:  Suzanne C Danhauer; Elizabeth L Addington; Lorenzo Cohen; Stephanie J Sohl; Marieke Van Puymbroeck; Natalia K Albinati; S Nicole Culos-Reed
Journal:  Cancer       Date:  2019-04-01       Impact factor: 6.860

2.  Are Perceived Stress and Cytokine Genotypes Clinically Feasible as Predictors of Psychoneuroimmune Symptoms in Advanced Cancer?

Authors:  Stephanie Gilbertson-White; Ariana Shahnazi; Catherine Cherwin
Journal:  Perm J       Date:  2019-07-08

3.  The Influence of Multiple Chronic Conditions on Symptom Clusters in People With Solid Tumor Cancers.

Authors:  Seyedehtanaz Saeidzadeh; Yelena Perkhounkova; Stephanie Gilbertson-White; Catherine H Cherwin
Journal:  Cancer Nurs       Date:  2022 Jan-Feb 01       Impact factor: 2.760

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.